Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 3, 2015, Pages 521-526

  Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Mori, Keita ^a   Ko, Ryo ^a   Ono, Akira ^a   Wakuda, Kazushige ^a   Imai, Hisao ^a   Taira, Tetsuhiko ^a   Murakami, Haruyasu ^a   Endo, Masahiro ^a   Takahashi, Toshiaki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Exacerbation; Interstitial lung disease; Lung cancer; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NAVELBINE; NEDAPLATIN; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84925485577     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2670-y     Document Type: Article

References (28)

1. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388
2. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128
3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
4. Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-Positive lung cancer. N Engl J Med 368:2385-2394
5. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18-S23
6. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348-1357
7. Azzoli CG, Temin S, Aliff T et al (2011) 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825-3831
8. Besse B, Adjei A, Baas P et al (2014) 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 25:1475-1484
9. Pavlakis N, Bell DR, Millward MJ et al (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286-291
10. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847-853
11. Yoh K, Kenmotsu H, Yamaguchi Y et al (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5:1435-1438
12. Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6:1242-1246
13. Collard HR, Moore BB, Flaherty KR et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636-643
14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
15. Shukuya T, Ishiwata T, Hara M et al (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30:4357-4361
16. Kinoshita T, Azuma K, Sasada T et al (2012) Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 4:477-482
17. Okuda K, Hirose T, Oki Y et al (2012) Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res 32:5475-5480
18. Watanabe N, Taniguchi H, Kondoh Y et al (2013) Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration 85:326-331
19. Minegishi Y, Takenaka K, Mizutani H et al (2009) Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 48:665-672
20. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323
21. Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28:5240-5246
22. Ohe Y, Yamamoto S, Suzuki K et al (2001) Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37:54-63
23. Sanuki N, Ono A, Komatsu E et al (2012) Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res 53:110-116
24. Minegishi Y, Sudoh J, Kuribayasi H et al (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71:70-74
25. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
26. Tamiya A, Naito T, Miura S et al (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32:1103-1106
27. Kuribayashi K, Voss S, Nishiuma S et al (2012) Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Lung Cancer 75:353-359
28. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277-304